Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer-Reference-Cited by-同舟云学术

Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer

Published:2020-06-25 Issue:8 Volume:29 Page:779-792
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Evangelisti Giulio¹²^ORCID,Barra Fabio¹²^ORCID,Moioli Melita¹²,Sala Paolo³⁴^ORCID,Stigliani Sara¹²,Gustavino Claudio³,Costantini Sergio¹²,Ferrero Simone¹²^ORCID

Affiliation:

1. Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino , Genoa, Italy

2. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child, Health (Dinogmi), University of Genoa , Italy

3. Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino , Genoa, Italy

4. LILT - Lega Italiana per la Lotta contro i Tumori, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1783238

Reference100 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

2. Cancer statistics, 2018

3. Surgical treatment: Myomectomy and hysterectomy; Endoscopy: A major advancement

4. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

2. Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition;Blood Cancer Discovery;2024-06-07

3. NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers;Cell Chemical Biology;2024-06

4. Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-Seq and Bulk RNA-Seq Analysis in GC;Recent Patents on Anti-Cancer Drug Discovery;2023-10-03

5. Nuak kinase signaling in development and disease of the central nervous system;Cellular Signalling;2022-12